 |
|
|
CUE Description — Cue Biopharma Inc
Cue Biopharma is a clinical-stage biopharmaceutical company. Co.'s proprietary Immuno-Selective Targeting and Alteration of T Cells (Immuno-STAT™) platform, enable Co. to restore health while avoiding the side effects of immune activation in the case of cancer and immune suppression in the case of autoimmune disease. Co. focused its internal resources on drug product candidates in its CUE-100 series of Immuno-STATs. The CUE-100 series uses the selectivity of the T cell receptor combined with rationally engineered interleukin 2 in context of the core Immuno-STAT framework for selective activation of targeted tumor-specific T cells to potentially address a range of cancers.
| Company Name: |
Cue Biopharma Inc |
| Website: |
www.cuebiopharma.com |
| Sector: |
Drugs & Pharmaceuticals |
| Number of ETFs Holding CUE: |
11 |
| Total Market Value Held by ETFs: |
$6,383,637 |
| Total Market Capitalization: |
$86,000,000 |
| % of Market Cap. Held by ETFs: |
7.42% |
|
| ETF |
CUE Weight |
CUE Amount |
| VTI |
0.00% |
$2,586,390 |
| IWM |
0.00% |
$1,576,349 |
| VXF |
0.00% |
$1,147,332 |
| IWO |
0.01% |
$592,257 |
| VTWO |
0.00% |
$260,671 |
| IWC |
0.02% |
$142,950 |
| VTWG |
0.01% |
$59,604 |
| VTHR |
0.00% |
$8,346 |
| URTY |
0.00% |
$5,482 |
| UWM |
0.00% |
$4,124 |
| List of all 11 ETFs holding CUE
» |
|
|
|
|
|
Strong Buy (4.00 out of 4)
94th percentile
|
|
|
Free CUE Email Alerts:
